Relevium Targets 30 New Bioganix® Gold Products in Walmart by Year End and Prepares to Launch in Canada
October 11 2018 - 8:46AM
MONTREAL, Oct. 11, 2018 (GLOBE NEWSWIRE) --
Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and
Frankfurt: “6BX”) (the “Company”
or “Relevium”),
announced its plans to increase its presence in Walmart.com and
ramp up its current offering to over thirty (30) SKUs before the
end of the year.
Following the successful initial test launch of
three (3) SKUs, the Company is now ready to introduce up to thirty
(30) new SKUs of its Bioganix® Gold Series formulated products
before the end of this year. The Company has also begun the
regulatory and compliance process to launch its formulated products
in the Canadian market and plans to test walmart.ca as
soon as the products obtain natural health product approvals from
Health Canada.
"Following an initial market testing period, we
are now expanding our presence in walmart.com to over thirty (30)
SKUs and we are targeting walmart.ca platform for the initial
launch of the Bioganix® Gold Series brand into the Canadian market”
stated Abis Hussain, Chief Marketing Officer.
“We are working through the regulatory process
to launch two (2) exclusive science based formulated products into
the Canadian market and we are monitoring Walmart’s recently
announced intention to explore the cannabis infused market as we
see this as a potential platform for our LeefyLyfe® brand for North
America” stated Aurelio Useche, Chief Executive Officer
The Company continues to make significant
progress in its OTC nutraceutical formulated business and recently
announced a line of hemp derived organic CBD infused products under
the LeefyLyfe® brand for the European market.
About Relevium Technologies
Relevium is a publicly-traded company that
operates in the health and wellness industry, a
multi-billion-dollar market worldwide.
Relevium markets its products as dietary
supplements, nutraceuticals, sports nutrition and
nutri-cosmeceuticals. The Company plans on unveiling a complete
line of dietary supplements for consumers derived from Cannabis
Sativa and Cannabis Indica. The Company’s initial focus will be on
creating a full spectrum extract rich in CBD (cannabidiol) which
will be marketed and sold throughout North America. Relevium is
also focused on developing a complete line of supplements,
nutraceuticals, sports nutrition and nutri-cosmeceuticals.
Relevium’s products and brands such as Bioganix® have achieved
market penetration and now sold at some of the world’s largest
retailers such as Walmart.com.
Relevium is also focused on the development,
acquisition, marketing and sale of consumer products that are
derived from cannabis and industrial hemp and other ingredients
that are generally accepted as safe. The Company uses cannabinoids
and ingredients that have achieved GRAS status (generally accepted
as safe) to create brands that are sold via wholesale channels,
retail channels and online distribution.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in policies
of the TSX Venture Exchange) accepts responsibility for the
adequacy or accuracy of this release.
Cautionary Note Regarding
Forward-Looking Statements
This release includes certain statements and information that may
constitute forward-looking information within the meaning of
applicable Canadian securities laws. All statements in this news
release, other than statements of historical facts, including
statements regarding future estimates, plans, objectives,
assumptions or expectations of future performance, including the
timing and completion of the proposed acquisitions, are
forward-looking statements and contain forward-looking information.
Generally, forward- looking statements and information can be
identified by the use of forward-looking terminology such as
"intends" or "anticipates", or variations of such words and phrases
or statements that certain actions, events or results "may",
"could", "should", "would" or "occur". Forward-looking statements
are based on certain material assumptions and analysis made by the
Company and the opinions and estimates of management as of the date
of this press release, including the assumptions that the Company
will be able to apply for and ultimately obtain an ACMPR licence,
the proposed business of Biocannabix will develop as anticipated,
that the Company will raise sufficient funds to develop the
Biocannabix business, and that the Company will obtain all
requisite regulatory approvals. These forward-looking statements
are subject to known and unknown risks, uncertainties and other
factors that may cause the actual results, level of activity,
performance or achievements of the Company to be materially
different from those expressed or implied by such forward-looking
statements or forward-looking information. Important factors that
may cause actual results to vary, include, without limitation, the
risk that the proposed business developments may not occur as
planned; the timing and receipt of requisite approvals and failure
to raise sufficient funds. Although management of the Company has
attempted to identify important factors that could cause actual
results to differ materially from those contained in
forward-looking statements or forward-looking information, there
may be other factors that cause results not to be as anticipated,
estimated or intended. There can be no assurance that such
statements will prove to be accurate, as actual results and future
events could differ materially from those anticipated in such
statements. Accordingly, readers should not place undue reliance on
forward- looking statements and forward-looking information.
Readers are cautioned that reliance on such information may not be
appropriate for other purposes. The Company does not undertake to
update any forward-looking statement, forward-looking information
or financial outlook that are incorporated by reference herein,
except in accordance with applicable securities laws. We seek safe
harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES
INC.
Aurelio Useche
President and CEO
For more information about this press
release:
Tel: +1.888.528.8687
RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
Like us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Relevium Technologies (CE) (USOTC:RLLVF)
Historical Stock Chart
From Nov 2024 to Dec 2024
Relevium Technologies (CE) (USOTC:RLLVF)
Historical Stock Chart
From Dec 2023 to Dec 2024